KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Receivables (2016 - 2024)

Nektar Therapeutics has reported Change in Receivables over the past 15 years, most recently at $2.2 million for Q4 2024.

  • Quarterly results put Change in Receivables at $2.2 million for Q4 2024, up 320.62% from a year ago — trailing twelve months through Sep 2025 was $2.2 million (up 1494.94% YoY), and the annual figure for FY2024 was $3.0 million, up 163.76%.
  • Change in Receivables for Q4 2024 was $2.2 million at Nektar Therapeutics, up from $850000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for NKTR hit a ceiling of $7.7 million in Q1 2022 and a floor of -$20.2 million in Q2 2022.
  • Median Change in Receivables over the past 5 years was -$642000.0 (2021), compared with a mean of -$1.6 million.
  • Biggest five-year swings in Change in Receivables: surged 1739.18% in 2020 and later plummeted 6992.63% in 2022.
  • Nektar Therapeutics' Change in Receivables stood at -$8.0 million in 2020, then surged by 68.87% to -$2.5 million in 2021, then plummeted by 121.86% to -$5.6 million in 2022, then skyrocketed by 82.0% to -$999000.0 in 2023, then surged by 320.62% to $2.2 million in 2024.
  • The last three reported values for Change in Receivables were $2.2 million (Q4 2024), $850000.0 (Q3 2024), and -$2.4 million (Q2 2024) per Business Quant data.